Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

Metformin and reduced risk of cancer in diabetic patients

Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388

Metformin

Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726

Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade

Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, D. R., & Hardie, D. G. (2003) · Journal of Biology · doi:10.1186/1475-4924-2-28 · Cited by 1,694

Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus

DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368

A chronic disease score from automated pharmacy data

Korff, M. V., Wagner, E. H., & Saunders, K. W. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90016-g · Cited by 962

Insulin and colon cancer

Giovannucci, E. L. (1995) · Cancer Causes & Control · doi:10.1007/bf00052777 · Cited by 808

Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults

Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J. M., & Thun, M. J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh161 · Cited by 795

Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis

Everhart, J. (1995) · JAMA · doi:10.1001/jama.273.20.1605 · Cited by 747

Decreased Mortality Associated With the Use of Metformin Compared With Sulfonylurea Monotherapy in Type 2 Diabetes

Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421

Prospective Study of Adult Onset Diabetes Mellitus (Type 2) and Risk of Colorectal Cancer in Women

Hu, F. B., Manson, J. E., Liu, S., Hunter, D. J., Colditz, G. A., Michels, K. B., Speizer, F. E., & Giovannucci, E. L. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.542 · Cited by 420

Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?

Campbell, I. W. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02292.x · Cited by 25

Colorectal Cancer: Histopathologic Differences in Tumor Characteristics Between Patients With and Without Diabetes

Sharma, A., Ng, H., Kumar, A., Teli, K., Randhawa, J., Record, J., & Maroules, M. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.10.002 · Cited by 29

The Oncojanus Paradigm of Respiratory Complex I

Leone, G., Abla, H., Gasparre, G., Porcelli, A. M., & Iommarini, L. (2018) · Genes · doi:10.3390/genes9050243 · Cited by 27

Respiratory Capacity and Reserve Predict Cell Sensitivity to Mitochondria Inhibitors: Mechanism-Based Markers to Identify Metformin-Responsive Cancers

Teh, J. T., Zhu, W., Newgard, C. B., Casey, P. J., & Wang, M. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0766 · Cited by 27

Metformin Dysregulates the Unfolded Protein Response and the WNT/β-Catenin Pathway in Endometrial Cancer Cells through an AMPK-Independent Mechanism

Conza, D., Mirra, P., Calı̀, G., Insabato, L., Fiory, F., Bèguinot, F., & Ulianich, L. (2021) · Cells · doi:10.3390/cells10051067 · Cited by 27

Do Diabetes Drugs Modify the Risk of Pancreatic Cancer?

Yang, Y. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.022 · Cited by 26

Effects of chronic hyperinsulinemia in insulin-resistant patients

Muntoni, S., Muntoni, S., & Draznin, B. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0040-z · Cited by 26

Diabetes and the risk for colorectal cancer

Erbach, M., Mehnert, H., & Schnell, O. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.11.003 · Cited by 26

Association between glucose‐lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy

Noh, Y., Jeon, S., & Shin, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.31870 · Cited by 28

Pancreatic Disorders and Diabetes Mellitus

Meisterfeld, R., Ehehalt, F., Saeger, H., & Solimena, M. (2008) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2008-1080918 · Cited by 26

Hyperglycemia-driven signaling bridges between diabetes and cancer

Ghareghomi, S., Arghavani, P., Mahdavi, M., Khatibi, A., García‐Jiménez, C., & Moosavi‐Movahedi, A. A. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116450 · Cited by 29

Insulin Glargine and NPH Insulin Increase to a Similar Degree Epithelial Cell Proliferation and Aberrant Crypt Foci Formation in Colons of Diabetic Mice

Nagel, J. M., Staffa, J., Renner‐Müller, I., Horst, D. A., Vogeser, M., Langkamp, M., Hoeflich, A., Göke, B., Kolligs, F. T., & Mantzoros, C. S. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0020-z · Cited by 25

Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk

Gao, R., Yang, T., & Xu, W. G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1333104 · Cited by 24

Do we have enough data to confirm the link between antidiabetic drug use and cancer development?

Drzewoski, J., Drozdowska, A., & Śliwińska, A. (2011) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1029 · Cited by 25

Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes

Hagberg, K. W., McGlynn, K. A., Sahasrabuddhe, V. V., & Jick, S. S. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.447 · Cited by 25

Sulfonylureas: do we need to introspect safety again?

Sehra, D., Sehra, S., & Sehra, S. T. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.583234 · Cited by 25

Prognostic significance of anti-diabetic medications in pancreatic cancer: A meta-analysis

Zhou, D.-C., Gong, H., Tan, C., & Luo, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17728 · Cited by 25

Glucose‐lowering medications and the risk of cancer: A methodological review of studies based on real‐world data

Bykov, K., He, M., Franklin, J. M., Garry, E. M., Seeger, J. D., & Patorno, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13766 · Cited by 25

Metformin and survival in diabetic patients with breast cancer

El-Benhawy, S. A., & Elsheredy, H. (2014) · Journal of the Egyptian Public Health Association · doi:10.1097/01.epx.0000456620.00173.c0 · Cited by 25

Losartan reduces oxidative damage to renal DNA and conserves plasma antioxidant capacity in diabetic rats

Lodovici, M., Bigagli, E., Tarantini, F., Serio, C. D., & Raimondi, L. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215570826 · Cited by 24

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

MacKay, H. J., Levine, D. A., Bae-Jump, V. L., Bell, D. W., McAlpine, J. N., Santin, A. D., Fleming, G. F., Mutch, D. G., Nephew, K. P., Wentzensen, N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19961 · Cited by 25

Dihydroquinazolin-4(1H)-one derivatives as novel and potential leads for diabetic management

Babatunde, O., Hameed, S., Salar, U., Chigurupati, S., Wadood, A., Rehman, A. U., Venugopal, V., Khan, K. M., Taha, M., & Perveen, S. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10196-5 · Cited by 24

Effect of frequently prescribed drugs on gastric cancer risk

Weltermann, T., Schulz, C., & Macke, L. (2021) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2021.101741 · Cited by 25

The Past and Future of Inflammation as a Target to Cancer Prevention

Antonucci, L., & Karin, M. (2024) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-23-0423 · Cited by 26

Glucose Metabolism Disorders and the Risk of Cancer

Piątkiewicz, P., & Czech, A. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0119-0 · Cited by 26

Comparative effectiveness for oral anti-diabetic treatments among newly diagnosed type 2 diabetics: data-driven predictive analytics in healthcare

Maguire, J., & Dhar, V. (2012) · Health Systems · doi:10.1057/hs.2012.20 · Cited by 23

MYC and AMPK–Save Energy or Die!

Haikala, H. M., Anttila, J. M., & Klefström, J. T. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00038 · Cited by 25

The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS)

Suzuki, Y., Enokido, Y., Yamada, K., Inaba, M., Kuwata, K., Hanada, N., Morishita, T., Mizuno, S., & Wakamatsu, N. (2017) · Oncotarget · doi:10.18632/oncotarget.17566 · Cited by 24

Co-Treatment with Sulforaphane and Nano-Metformin Molecules Accelerates Apoptosis in HER2+ Breast Cancer Cells by Inhibiting Key Molecules

Keshandehghan, A., Nikkhah, S., Tahermansouri, H., Keshel, S. H., & Gardaneh, M. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1655073 · Cited by 24

A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer

Dulskas, A., Patašius, A., Linkevičiūtė-Ulinskienė, D., Zabulienė, L., & Smailytė, G. (2019) · Aging · doi:10.18632/aging.102245 · Cited by 24

The Chemosensitizing Role of Metformin in Anti-Cancer Therapy

Tang, Z., Tang, N., Jiang, S., Bai, Y., Guan, C., Zhang, W., Fan, S., Huang, Y., Lin, H., & Ying, Y. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200918102642 · Cited by 24

Glucose tolerance status and 20 year cancer incidence.

Dankner, R. S., Chetrit, A., & Segal, P. (2007) · PubMed · Cited by 24

Prognosis of Hormone-Dependent Breast Cancers: Implications of the Presence of Dysfunctional Transcriptional Networks Activated by Insulin via the Immune Transcription Factor T-bet

McCune, K. R., Bhat‐Nakshatri, P., Thorat, M. A., Nephew, K. P., Badve, S., & Nakshatri, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1530 · Cited by 23

Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin

Aksoy, S., Şendur, M. A. N., & Altundağ, K. (2013) · Medical Oncology · doi:10.1007/s12032-013-0590-z · Cited by 24

Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy’s safety profile

Schwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 24

Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma

Nakayama, A., Ninomiya, I., Harada, S., Tsukada, T., Okamoto, K., Nakanuma, S., Sakai, S., Makino, I., Kinoshita, J., Hayashi, H., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3676 · Cited by 23

Insulin resistance and adrenal incidentalomas: A bidirectional relationship

Sydney, G. I., Ioakim, K. J., & Paschou, S. Α. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.12.002 · Cited by 23

Metformin, Cancer, Alphabet Soup, and the Role of Epidemiology in Etiologic Research

Duncan, B. B., & Schmidt, M. I. (2009) · Diabetes Care · doi:10.2337/dc09-1183 · Cited by 23

Metformin and Colorectal Cancer Risk in Diabetic Patients

Ioannou, G. N., & Boyko, E. J. (2011) · Diabetes Care · doi:10.2337/dc11-1447 · Cited by 23

Current and Emerging Treatment Options in Diabetes Care

Clemmensen, C., Müller, T. D., Finan, B., Tschöp, M. H., & DiMarchi, R. D. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_7 · Cited by 22

Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma

Cheng, J. J. S., Li, H., Tan, H. S., Tan, P. H., Ng, L. G., Ng, Q. S., Toh, C., Kanesvaran, R., & Tan, M. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.12.012 · Cited by 22

Association of Diabetes with Oral Cancer- an Enigmatic Correlation

Mekala, M. R., Bangi, B. B., Jayalatha, N., Lebaka, R., Nadendla, L. K., & Ginjupally, U. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.3.809 · Cited by 22

Clinical benefits of metformin in gynecologic oncology

Imai, A., Ichigo, S., Matsunami, K., TAKAGI, H., & Yasuda, K. (2015) · Oncology Letters · doi:10.3892/ol.2015.3262 · Cited by 22

Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer

Suissa, S. (2012) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10082 · Cited by 23

Metabolic Syndrome as a Peculiar Target for Management of Prostate Cancer Patients

Conteduca, V., Lorenzo, G. D., Bozza, G., Ardito, R., & Aieta, M. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.04.009 · Cited by 22

Basal insulin analogs: From pathophysiology to therapy. What we see, know, and try to comprehend?

Monnier, L., Colette, C., & Owens, D. R. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.003 · Cited by 22

Medically Managed Hypercholesterolemia and Insulin-Dependent Diabetes Mellitus Preoperatively Predicts Poor Survival after Surgery for Pancreatic Cancer

Chagpar, R., Martin, R. C. G., Ahmad, S. A., Kim, H. J., Rupp, C. C., Weber, S., Ebelhar, A. J., Gilbert, J. E., Brinkman, A. S., Winslow, E. R., et al. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1448-3 · Cited by 22

Management of colorectal cancer and diabetes

Yao, C., Nash, G. F., & Hickish, T. (2013) · Journal of the Royal Society of Medicine · doi:10.1177/0141076813512121 · Cited by 22

Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients

Goossens, M. E., Buntinx, F., Zeegers, M. P., Driessen, J. H. M., Bruin, M. L. D., & de Vries, F. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12740 · Cited by 22

Vasculotoxic Effects of Insulin and Its Role in Atherosclerosis: What is the Evidence?

Nandish, S., Bailon, O., Wyatt, J., Smith, J., Stevens, A., Lujan, M., & CHILTON, R. J. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0165-4 · Cited by 22

GRADE-Leitlinien: 4. Bewertung der Qualität der Evidenz – Studienlimitationen (Risiko für Bias)

Meerpohl, J. J., Langer, G., Perleth, M., Gartlehner, G., Kaminski-Hartenthaler, A., & Schünemann, H. J. (2012) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2012.06.014 · Cited by 21

An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin

Tardón, M. C., Marinari, E., Migliorini, D., Bes, V., Tankov, S., Charrier, E., McKee, T., Dutoit, V., Dietrich, P., Cosset, E. C., et al. (2020) · Biology · doi:10.3390/biology9090264 · Cited by 21

Diabetes and cancer relationships (糖尿病与肿瘤的关联性)

Wang, T., Ning, G., & Bloomgarden, Z. T. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12057 · Cited by 21

The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway

Li, B., Takeda, T., Tsuiji, K., Kondo, A., Kitamura, M., Wong, T. F., & Yaegashi, N. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.706668 · Cited by 21

Glioma Stem Cells: Markers, Hallmarks and Therapeutic Targeting by Metformin

Najbauer, J., Kraljik, N., & Németh, P. (2014) · Pathology & Oncology Research · doi:10.1007/s12253-014-9837-z · Cited by 21

Type 2 Diabetes Mellitus, Oral Diabetic Medications, Insulin Therapy, and Overall Breast Cancer Risk

Ahmadieh, H., & Azar, S. T. (2013) · ISRN Endocrinology · doi:10.1155/2013/181240 · Cited by 21

Anti-Diabetic Medications Do Not Influence Risk of Lung Cancer in Patients with Diabetes Mellitus: a Systematic Review and Meta-analysis

Nie, S., Chen, H., Zhuang, M., & Lü, M. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.16.6863 · Cited by 21

Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma

Costanzo, G. G. D., Tortora, R., Morisco, F., Addario, L., Guarino, M., Cordone, G., Falco, L., & Caporaso, N. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0454-5 · Cited by 21

Effect of metformin on hepatocellular carcinoma patients with type II diabetes receiving transarterial chemoembolization: a multicenter retrospective cohort study

Chen, L., Wu, L., Zhang, L., Sun, B., Wu, W., Yu, L., Zhu, L., Sun, T., Liang, B., Zhao, H., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001872 · Cited by 20

Metformin: risk-benefit profile with a focus on cancer

Provinciali, N., Lazzeroni, M., Cazzaniga, M., Gorlero, F., Dunn, B. K., & DeCensi, A. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1084289 · Cited by 21

Biological Effects of Calorie Restriction: Implications for Modification of Human Aging

Spindler, S. R. (2010) · Springer eBooks · doi:10.1007/978-90-481-3999-6_12 · Cited by 20

Exercise—A Panacea of Metabolic Dysregulation in Cancer: Physiological and Molecular Insights

Raun, S. H., Buch‐Larsen, K., Schwarz, P., & Sylow, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073469 · Cited by 20

Insulin Therapy and Cancer in Type 2 Diabetes

Mannucci, E. (2012) · ISRN Endocrinology · doi:10.5402/2012/240634 · Cited by 21

Targeting the Latest Hallmark of Cancer: Another Attempt at ‘Magic Bullet’ Drugs Targeting Cancers’ Metabolic phenotype

Čuperlović‐Culf, M., Culf, A. S., Touaibia, M., & Lefort, N. (2012) · Future Oncology · doi:10.2217/fon.12.121 · Cited by 21

Diabetes Mellitus as a Novel Risk Factor for Gastrointestinal Malignancies

Herrigel, D. J., & Moss, R. A. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2825 · Cited by 20

Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin

Wang, F., Ding, X., Wang, T., Shan, Z., Wang, J., Wu, S., Chi, Y., Zhang, Y., Lv, Z., Wang, L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174276 · Cited by 20

Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs

Hung, M., Chuang, M., Chen, Y.-C., Lee, C.-P., Yang, T., Chen, P., Tsai, Y., & Yang, Y. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419869491 · Cited by 20

A Cohort Study of Antihyperglycemic Medication Exposure and Gastric Cancer Risk

Dulskas, A., Patašius, A., Kačėnienė, A., Linkevičiūtė-Ulinskienė, D., Zabulienė, L., & Smailytė, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020435 · Cited by 20

Cancer metabolism as a therapeutic target.

Batra, S., Adekola, K., Rosen, S. T., & Shanmugam, M. (2013) · PubMed · Cited by 20

Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?

de Heer, J., & Göke, B. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.955013 · Cited by 19

Insulin Pumps and Their Use in Pregnancy

Wollitzer, A. D., Zisser, H., & Jovanovič, L. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0187 · Cited by 19

Patients With Type 2 Diabetes: Anesthetic Management in the Ambulatory Setting: Part 2: Pharmacology and Guidelines for Perioperative Management

Cornelius, B. W. (2017) · Anesthesia Progress · doi:10.2344/anpr-64-01-02 · Cited by 20

Missing the benefit of metformin in acute myeloid leukemia: A problem of contrast?

Ceacareanu, A. C., Nimako, G. K., & Wintrob, Z. A. P. (2017) · Journal of Research in Pharmacy Practice · doi:10.4103/jrpp.jrpp_17_37 · Cited by 19

Anti-Diabetic Drugs: Cure or Risk Factors for Cancer?

Laskar, J., Bhattacharjee, K., Sengupta, M., & Choudhury, Y. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0402-z · Cited by 20

The addition of metformin to systemic anticancer therapy in advanced or metastatic cancers: a meta-analysis of randomized controlled trials

Kim, H. S., Kim, J. H., Jang, H. J., & Lee, J. Y. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.50338 · Cited by 19

Diabetes and risk of tumors: oncologic considerations

Rosta, A. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29158 · Cited by 19

Metformin reduces the Walker-256 tumor development in obese-MSG rats via AMPK and FOXO3a

de Queiroz, E. A. I. F., Akamine, E. H., de Carvalho, M. H. C., Sampaio, S. C., & Fortes, Z. B. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.11.028 · Cited by 19

Prognostic value of serum liver enzymes levels in type 2 diabetic patients

Monami, M., Balzi, D., Lamanna, C., Melani, C., Cocca, C., Lotti, E., Fedeli, A., Masotti, G., Marchionni, N., & Mannucci, E. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.744 · Cited by 19

AMP-Activated Protein Kinase

Hardie, D. G. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00073-5 · Cited by 19

Lifestyle and Pharmacologic Approaches to Prevention of Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma

Cheraghpour, M., Hatami, B., & Singal, A. G. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.09.041 · Cited by 19

Efecto hipoglicemiante coadyuvante del extracto etanólico de hojas de Annona muricata L (guanábana), en pacientes con diabetes tipo 2 bajo tratamiento de glibenclamida

Arroyo, J. L., Martínez, J., Ronceros, G., Palomino, R., Villarreal, A., Bonilla, P. E., Palomino, C., & Florentini, M. G. Q. (2012) · Anales de la Facultad de Medicina · doi:10.15381/anales.v70i3.934 · Cited by 18

Association of fasting serum insulin and cancer mortality in a healthy population – 28-year follow-up of the French TELECOM Study

Wargny, M., Balkau, B., Lange, C., Charles, M.-A. A., Giral, P., & Simon, D. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.03.006 · Cited by 19

Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer

Bora, V. R., & Patel, B. M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119329 · Cited by 18

Metformin, Insulin, Breast Cancer and More…

Berstein, L. M. (2009) · Future Oncology · doi:10.2217/fon.09.2 · Cited by 18

Omega-3 free fatty acids attenuate insulin-promoted breast cancer cell proliferation

Guo, Y., Zhu, S., Wu, Y., He, Z., & Chen, Y. Q. (2017) · Nutrition Research · doi:10.1016/j.nutres.2017.04.008 · Cited by 18

Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires

Zhuang, Y., & Miskimins, W. K. (2008) · Cited by 18

Insulin therapy in diabetes and cancer risk: Current understanding and implications for future study

Gough, S. C. L., Belda-Iniesta, C., Poole, C., Weber, M. M., Russell-Jones, D. L., Hansen, B. F., Mannucci, E., & Tuomilehto, J. O. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0047-8 · Cited by 17

Activated Carbon nanoparticles Loaded with Metformin for Effective Against Hepatocellular Cancer Stem Cells

Sun, L., Yao, H.-J., Li, J.-C., Zhao, B., Wang, Y., & Zhang, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s382519 · Cited by 17

Endogenous hyperinsulinaemia and exogenous insulin: A common theme between atherosclerosis, increased cancer risk and other morbidities

Holden, S. E., & Currie, C. J. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.01.052 · Cited by 17

Design of an Insulin Analog with Enhanced Receptor Binding Selectivity

Zhao, M., Wan, Z., Whittaker, L. J., Xu, B., Phillips, N. B., Katsoyannis, P. G., Ismail‐Beigi, F., Whittaker, J., & Weiss, M. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.028399 · Cited by 16

Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients – a retrospective study of clinical and tumor characteristics

Bešič, N., Šatej, N., Ratoša, I., Horvat, A. G., Marinko, T., Gazić, B., & Petrič, R. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-298 · Cited by 17

Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study

Feng, J., & Qin, X. S. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108755 · Cited by 17

Targeting Hypoxia: Revival of Old Remedies

Vilaplana‐Lopera, N., Besh, M., & Moon, E. J. (2021) · Biomolecules · doi:10.3390/biom11111604 · Cited by 17

The Effect of Metformin on Responses to Chemotherapy and Survival in Stage IV Colorectal Cancer with Diabetes

Lee, D.-J., Kim, B., Lee, J. H., Park, S. J., Hong, S. P., Cheon, J. H., Kim, T. I., & Kim, W. H. (2012) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2012.60.6.355 · Cited by 17

Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective

Yang, H., Wu, C.-Y., Powell, J. D., & Lu, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114030 · Cited by 17

Gender‐specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus

Sun, G. E. C., Wells, B. J., Yip, K., Zimmerman, R. S., Raghavan, D., Kattan, M. W., & Kashyap, S. R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12231 · Cited by 16

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly

Varewijck, A. J., Janssen, J. A. M. J. L., Vähätalo, M., Hofland, L. J., Lamberts, S. W. J., & Yki‐Järvinen, H. (2012) · Diabetologia · doi:10.1007/s00125-011-2435-7 · Cited by 16

The influence of metformin in the etiology of selected cancers

Pawałowska, M., & Markowska, A. (2012) · Współczesna Onkologia · doi:10.5114/wo.2012.29289 · Cited by 16

Risk of Endometrial Cancer in Women with Diabetes: A Population-Based Retrospective Cohort Study

Zabulienė, L., Kačėnienė, A., Steponavičienė, L., Linkevičiūtė-Ulinskienė, D., Stukas, R., Arlauskas, R., Vansevičiūtė-Petkevičienė, R., & Smailytė, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163453 · Cited by 16

North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations

Alhusayen, R. O., Dienes, S., Lam, M., Alavi, A., Alikhan, A., Aleshin, M. A., Bahashwan, E., Daveluy, S. D., Goldfarb, N. I., Garg, A., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.11.071 · Cited by 16

Antidiabetic agents and cancer outcomes: Are there differences between agents?

Bowker, S. L. (2009) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r31s9h

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure

Bowker, S. L., Yasui, Y., Veugelers, P. J., & Johnson, J. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1750-8 · Cited by 166

Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients

Bo, S., Ciccone, G., Rosato, R., Villois, P., Appendino, G., Ghigo, E., & Grassi, G. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01480.x · Cited by 87

Metformin and Cancer in Type 2 Diabetes

Park, H. K. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.2.113 · Cited by 16

Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort

Baur, D. M., Klotsche, J., Hamnvik, O. R., Sievers, C., Pieper, L., Wïttchen, H., Stalla, G. K., Schmid, R. M., Kales, S. N., & Mantzoros, C. S. (2010) · Metabolism · doi:10.1016/j.metabol.2010.09.012 · Cited by 90